Background
==========

*C. trachomatis* infection is the most common sexually transmitted disease (STD) in the United States \[[@B1]\]. Mounting evidence has indicated that it not only evokes nongonococcal urethritis (NGU), cervicitis, pelvic inflammatory disease (PID), salpingitis, orchitis, and epididymitis, but also increases risk of invasive cervical cancer \[[@B2],[@B3]\] and gives rise to serious reproductive disorders such as infertility \[[@B4],[@B5]\], miscarriage/premature birth/missed miscarriage \[[@B6]-[@B9]\], and neonatal conjunctivitis \[[@B10]\].

A large number of methods have been established for screening and diagnosis of *C. trachomatis* infection \[[@B11]\]. Nevertheless, few of these assays meet the requirements of outpatient diagnosis, especially in terms of sensitivity, specificity, time, and simplicity of operation. Currently, non-culture assays for *C. trachomatis* screening typically adopt immunochromatography-based methods. Technologies based on chromogenic reactions of specific microbial enzymes have been widely applied in bacterial identification systems and chromogenic media \[[@B12]-[@B15]\]. However, no chromogenic assay for detecting *C. trachomatis* has been made available to date.

Our previous findings \[[@B16]\] suggested that *C. trachomatis* might have very high α-mannosidase activity. The purpose of the study was to establish a novel screening method for *C. trachomatis* infection without culture that would be rapid and convenient for use in outpatient clinics.

Methods
=======

Ethics statement
----------------

All patients were treated in accordance with the Helsinki Declaration on the participation of human subjects in medical research. Ethics approval for the study was obtained from the First Affiliated Hospital Ethics Committee of Zhengzhou University (Approved No. 20100802) and Henan Provincial People's Hospital Ethics Committee (Approved No. 20100901).

Organisms
---------

Reference strains and cell lines were obtained from the organisations shown in Table [1](#T1){ref-type="table"}.

###### 

Reference strains and cell line

  **Strains or cell line**            **Accession numbers**   **Organizations**
  ----------------------------------- ----------------------- ---------------------------------------------------------------------------------
  *Acinetobacter baumannii*           ATCC19606               Harmony Biotechnology Co., Ltd (Shanghai, China)
  *Candida albicans*                  ATCC10231               Harmony Biotechnology Co., Ltd (Shanghai, China)
  *Candida glabrata*                  ATCC15126               Harmony Biotechnology Co., Ltd (Shanghai, China)
  *Candida guilliermondii*            ATCC6260                Harmony Biotechnology Co., Ltd (Shanghai, China)
  *Candida krusei*                    ATCC14243               Harmony Biotechnology Co., Ltd (Shanghai, China)
  *Cryptococcus neoformans*           CMCC(F)D2q              China Medical Microbiological Culture Collection Center (fungi)(Nanjing, China)
  *Candida parapsilosis*              CGMCC2.1846             China General Microbiological Culture Collection Center (Beijing, China)
  *Candida tropicalis*                ATCC750                 Harmony Biotechnology Co., Ltd (Shanghai, China)
  *Chlamydia trachomatis* Serovar D   VR-885                  American Type Culture Collection(Manassas, USA)
  *Enterococcus faecalis*             ATCC29212               Huankai Microbial Sci & Tech. Co., Ltd (Guangzhou, China)
  *Enterococcus faecium*              ATCC700221              Harmony Biotechnology Co., Ltd (Shanghai, China)
  *Escherichia coli*                  ATCC25922               Henan Provincial Institute of Food and Drug Control (Zhengzhou, China)
  *Gardnerella vaginalis*             ATCC14018               Harmony Biotechnology Co., Ltd (Shanghai, China)
  *Haemophilus influenzae*            ATCC10211               Harmony Biotechnology Co., Ltd (Shanghai, China)
  *Klebsiella pneumoniae*             CMCC46117               Tianhe Microorganism Reagent Co., Ltd (Hangzhou, China)
  McCony                              CRL-1696                American Type Culture Collection(Manassas, USA)
  *Mycoplasma hominis*                ATCC15488               Harmony Biotechnology Co., Ltd (Shanghai, China)
  *Neisseria gonorrhoeae*             ATCC19424               Henan Provincial Center for Disease Control and Prevention (Zhengzhou, China)
  *Pseudomonas aeruginosa*            ATCC25619               Land Bridge Biotechnology Co., Ltd (Beijing, China)
  *Proteus mirabilis*                 CMCC(B)49005            Huankai Microbial Sci & Tech. Co., Ltd (Guangzhou, China)
  *Salmonella enteritidis*            ATCC13076               Land Bridge Biotechnology Co., Ltd (Beijing, China)
  *Staphylococus aureus*              ATCC25923               Henan Provincial Institute of Food and Drug Control (Zhengzhou, China)
  *Staphylococcus aureus*             ATCC29213               Capital Institute of Pediatrics (Beijing, China)
  *Staphylococcus epidermidis*        ATCC12228               Huankai Microbial Sci & Tech. Co., Ltd (Guangzhou, China)
  *Staphylococus saprophyticus*       ATCC49453               Land Bridge Biotechnology Co., Ltd (Beijing, China)
  *Stenotrophomonas maltophilia*      ATCC17666               Land Bridge Biotechnology Co., Ltd (Beijing, China)
  *Streptococus agalactiae*           ATCC13813               Harmony Biotechnology Co., Ltd (Shanghai, China)
  *Streptococus pneumoniae*           ATCC49619               National Center for Clinical Laboratory (Beijing, China)
  *Streptococus pyogenes*             ATCC19615               Harmony Biotechnology Co., Ltd (Shanghai, China)
  *Trichomonas vaginalis*             ATCC30001               Harmony Biotechnology Co., Ltd (Shanghai, China)
  *Ureaplasma urealyticum*            ATCC15531               Harmony Biotechnology Co., Ltd (Shanghai, China)

Specimens
---------

This study evaluated 553 specimens from clinical patients attending the STD (257, 46.47%) and Gynaecology (296, 53.53%) clinics at the First Affiliated Hospital of Zhengzhou University (Zhengzhou, China) and the Henan Provincial People's Hospital (Zhengzhou, China), respectively. For the 203 male cases, three urethral discharge specimens (151 outpatients, 74.38%) or three prostate massage liquid specimens (52 outpatients, 25.62%) were collected with sterile rayon swabs (Copan, Brescia, Italy). Meanwhile, for the 350 female cases, three cervical secretion specimens (232 outpatients, 66.29%) or three vaginal secretion specimens (118 outpatients, 33.71%) were collected with sterile rayon swabs using vaginal forceps. Three swabs collected for each specimen, were no significant differences in sampling link and randomly used with three methods. None of the patients received any antibiotics one week before sample collection, when samples were taken before diagnosis.

Media, culture and inoculation
------------------------------

Liquid media A (LMA) and liquid media B (LMB) were prepared for mycoplasma culture. The components of LMA were shown in Table [2](#T2){ref-type="table"}, but LMB consisted of 50 mg/l phenol red besides LMA components. The media were inoculated with both *Ureaplasma urealyticum* and *Mycoplasma hominis* and analyzed by using the colour-changing unit (CCU) method, as previously reported \[[@B17]\]. Once the concentrations of mycoplasma reached 10^6^ CCU/ml in LMB, the cultures of LMA should be immediately stored at 4°C.

###### 

Composition of LMA for Mycoplasma (per liter) \*

  **Ingredient**            **Concentration**  **Ingredient**              **Concentration**
  ------------------------ ------------------- -------------------------- -------------------
  NaCl                            6.4 g        Beef heart extract power          7.2 g
  CaCl~2~                        112 mg        Yeast extract power              2.72 g
  MgCl~2~·6H~2~O                  80 mg        Peptone                           8.0 g
  MgSO~4~·7H~2~O                  80 mg        Horse serum                      200 ml
  KCl                            320 mg        Penicillin sodium            1,000,000 units
  Na~2~HPO~4~·12H~2~O            122 mg        Ampicillin sodium                375 mg
  KH~2~PO~4~                      48 mg        Vancomycin                        40 mg
  Cysteine hydrochloride          0.8 g        Polymyxin B                   40,000 units
  Arginine hydrochloride          4.0 g        Nystatin                    15,000 USP units
  Urea                            4.0 g                                             

\*Adjusted to pH 6.25.

*Trichomonas vaginalis* was obtained after 24 h incubation at 37°C in Trichomonas medium (Oxoid, Basingstoke, UK) supplemented with 8% horse blood and 1,000 units/ml penicillin sodium and 500 mg/ml streptomycin. The collection was stored at 4°C.

All other micro-organisms except *C. trachomatis* used in the study were inoculated and cultured as described in Table [3](#T3){ref-type="table"}. The collections described in Table [3](#T3){ref-type="table"} were resuspended to 0.5 McFarland standards in a sterile solution of 0.9% NaCl and then stored at 4°C.

###### 

The media and culture methods for bacteria and candida

  **Strains**                                           **Media**            **Temp.**   **Time**
  ------------------------------------------- ----------------------------- ----------- ----------
  **Bacteria**                                                                               
  *A. baumannii*, *E. faecalis*,                   Blood agar base ^a^         37°C        24 h
  *E. faecium*, *E. coli*, *K. pneumoniae*,                                             
  *P. mirabilis*, *P. aeruginosa*,                                                      
  *S. enteritidis*, *S. aureus*,                                                        
  *S. epidermidis*, *S. saprophyticus*,                                                 
  *S. maltophilia*, *S. agalactiae*,                                                    
  *S. pyogenes*, *S. pneumoniae*                                                        
  *G. vaginalis* \*                                  Blood agar base           37°C        48 h
  *H. influenzae* \*                             Thayer Martin media ^b^       24 h     
  *N. gonorrhoeae* \*                                     48 h                          
  **Candida**                                                                                
  *C. albicans*, *C. tropicalis*,              Sabouraud dextrose agar ^c^     37°C        24 h
  *C. glabrata*, *C. parapsilosis*,                                                     
  *C. guilliermondii*, *C. krusei*,                                                     
  *C. neoformans*                                         30°C                 48 h     

^a,b,c^ Oxoid, Basingstoke, UK; ^a^ supplemented with 5% sheep blood; ^b^ supplemented with 5% horse blood; \* cultured in a candle jar.

Enzymatic method
----------------

The enzymatic method was based on the substrate of α-D-mannosidase. The substrate solution contained 1.5 mg/ml 6-chloro-3-indolyl-α-D-mannoside (J&K, Shanghai, China), 100 mM citrate buffer (pH 4.0), and 1% Triton X-100. The sample diluent was 0.9% NaCl. The chromogenic reagent contained 0.08% fast violet B salt (J&K, Shanghai, China). Aliquots (50 μl) of substrate solution and chromogenic reagent were added sequentially into sample solutions (extracted from every swab sample with 500 μl sample diluent) or the aforementioned microbial suspensions as well as the chlamydial suspension mentioned in the section called limit of detection (LOD) of the enzymatic method. The result was considered to be positive (OD~512~ ≧ 0.150) if the colour changed from colourless to red or brown after 15 min of incubation at 37°C; otherwise, the result was considered to be negative (OD~512~ \< 0.150). The suspensions containing bacteria or cells was centrifuged at 5,000 rpm for 5 min, and then OD~512~ value of the supernatants were measured.

LOD of the enzymatic method
---------------------------

McCoy cells infected with *C. trachomatis* serovar D were stored at −80°C, and frozen-thawed twice to obtain chlamydial suspension before use. Serial 10-fold dilutions of the chlamydial suspension were inoculated in six duplicate into wells (100 μl/well) of cycloheximide-treated McCoy cell monolayers that had been incubated with MEM medium (Gibco, Grand Island, NY, USA) in a 96-well flat-bottom microtiter plate (Nunc Inc., Roskilde, Denmark) at 37°C under 5% CO~2~ for 48 h. Inclusion body titers of the chlamydial supernatant were quantified by titrating the number of inclusion-forming units (IFU). The contents of each well were stained with a *C. trachomatis* direct fluorescent antibody kit (Academy of Military Medical Science, Beijing, China) and examined by microscopy for IFU counts. The average IFU of each dilution culture of three replicate wells was taken as the concentration of *C. trachomatis* in the corresponding dilution of the chlamydia suspension. Each dilution culture of the other three replicate wells was examined via the enzymatic method after collection to determine the LOD for *C. trachomatis* of the enzymatic method. 10^-1^ u/ml α-D-mannosidase (EC3.2.1.24; Sigma, USA) solution was 5-fold serially diluted to 10^-4^ u/ml. These enzyme solutions fold-diluted were detected via the enzymatic method to determine the LOD for α-D-mannosidase.

Reference method
----------------

Cell culture and LCR method were used to evaluate the clinical performance of the enzymatic method. The swabs used for culture were dipped directly into incidental transport medium (Copan, Brescia, Italy) and cultured according to the aforementioned method. The cultures were tested using a *C. trachomatis* direct fluorescent antibody kit. LCR was carried out using the LCx *C. trachomatis* assay (Abbott Laboratories, Abbott Park, Israel) according to the manufacturer's instructions. Although culture method has a good specificity, its sensitivity may be influenced by various factors. Therefore, the research adopted an "expanded gold standard" \[[@B18]-[@B20]\] described as follows: any positive by either culture or LCR was classified as a true positive, whatever the result of the enzymatic method.

Results
=======

In our developed assay, only *C. trachomatis* samples tested was positive for α-D-mannosidase activity; but OD~512~ of both other organisms and cell cultures which were not inoculated with *C. trachomatis* used in the study was all below 0.100, which fell into the range of negative results negative with 0.150 (OD~512~) as the cut-off value, even if the reactions were allowed to proceed for 1 h at 37°C. Of the 553 clinical samples, 132 samples were positive with OD~512~ ranging from 0.161 to 1.955, and 421 samples were negative with OD~512~ ranging from 0.013 to 0.142. *C. trachomatis* detection results of 553 cases with culture, LCR and enzymatic method used an expanded gold standard as the reference standard were showed in Table [4](#T4){ref-type="table"}. The enzymatic method was least reliable when prostate specimens were used. The sensitivity of the enzymatic method was 91.5% (95% confidence interval \[CI\], 85.9% to 97.1%), and the specificity of this method was 90.0% (95% CI, 87.3% to 92.7%) (Table [5](#T5){ref-type="table"}). The sensitivity and specificity of the LCR were 94.7% (95% CI, 90.2% to 99.2%) and 100% (95% CI, 100.0% to 100.0%), respectively. However, in those specimens other than prostate fluid samples, the sensitivity and specificity of the enzymatic method were 91.8% (95% CI, 86.0% to 97.6%) and 98.3% (95% CI, 97.1% to 99.5%), in the meantime the sensitivity and specificity of the LCR were 95.3% (95% CI, 90.8% to 99.8%) and 100% (95% CI, 100% to 100%) (Table [6](#T6){ref-type="table"}), respectively. There were no significant differences in performance between the enzymatic method and the expanded gold standard (*P* \> 0.05).

###### 

***C. trachomatis*detection results of 553 cases with culture, LCR and enzymatic method used an expanded gold standard as the reference standard**

  **Method**               **No. of true positives/positives**   **No. of true negatives/negatives**
  ------------------------ ------------------------------------- -------------------------------------
  Enzymatic method         86/132                                413/421
                           Urethral discharge 22/24              Urethral discharge 126/127
                           Prostate massage liquid 8/47          Prostate massage liquid 4/5
                           Cervical secretion 31/33              Cervical secretion 196/199
                           Vaginal secretion 25/28               Vaginal secretion 87/90
  Cell culture             60/60                                 459/493
                           Urethral discharge 18/18              Urethral discharge 128/133
                           Prostate massage liquid 7/7           Prostate massage liquid 43/45
                           Cervical secretion 21/21              Cervical secretion 198/211
                           Vaginal secretion 14/14               Vaginal secretion 90/104
  LCR                      85/89                                 459/464
                           Urethral discharge 22/22              Urethral discharge 128/133
                           Prostate massage liquid 8/8           Prostate massage liquid 43/45
                           Cervical secretion 32/32              Cervical secretion 198/211
                           Vaginal secretion 27/27               Vaginal secretion 90/104
  Expanded gold standard   94                                    459
                           Urethral discharge 23                 Urethral discharge 128
                           Prostate massage liquid 9             Prostate massage liquid 43
                           Cervical secretion 34                 Cervical secretion 198
                           Vaginal secretion 28                  Vaginal secretion 90

###### 

**Clinical performances of three assays for*C. trachomatis*using specimens included prostate massage liquid**

  **Methods**            **% Sensitivity (95% CI)**   **% Specificity (95% CI)**
  --------------------- ---------------------------- ----------------------------
  Enzymatic method^a^        91.5 (85.9, 97.1)            90.0 (87.3, 92.7)
  Cell culture^b^            63.8 (54.1, 73.5)           100.0 (100.0, 100.0)
  LCR^c^                     94.7 (90.2, 99.2)           100.0 (100.0, 100.0)

^a^ Χ^2^ = 8.030, *P* = 0.005, *P* \< 0.05; ^b^ Χ^2^ = 8.721, *P* = 0.003, *P* \< 0.05; ^c^ Χ^2^ = 0.164, *P* = 0.685, *P* \> 0.05.

###### 

**Clinical performances of three assays for*C. trachomatis*using specimens excluded prostate massage liquid**

  **Methods**            **% Sensitivity (95% CI)**   **% Specificity (95% CI)**
  --------------------- ---------------------------- ----------------------------
  Enzymatic method^a^        91.8 (86.0, 97.6)            98.3 (97.1, 99.5)
  Cell culture^b^            64.6 (54.3, 74.9)           100.0 (100.0, 100.0)
  LCR^c^                     95.3 (90.8, 99.8)           100.0 (100.0, 100.0)

^a^ Χ^2^ = 0, *P* = 1, *P* \> 0.05; ^b^ Χ^2^ = 8.605, *P* = 0.003, *P* \< 0.05; ^c^ Χ^2^ = 0.116, *P* = 0.734, *P* \> 0.05.

The result of the chlamydial suspension quantified with 617 IFU/ml was light pink, and might be considered positive (OD~512~ = 0.162). Meanwhile, the result of the chlamydial suspension was colourless if quantified with 126 IFU/ml, and might be considered negative (OD~512~ = 0.098). Therefore, the LOD was 617 IFU/ml for *C. trachomatis*. In addition, the LOD was 10^-3^ u/ml (OD~512~ = 0.155) for α-D-mannosidase.

Discussion
==========

There are various well-known methods for detecting *C. trachomatis*, including cell culture-, immunology-, molecular biology-, and biochemistry-based methods. Cell culture is complicated to perform and requires experience to produce accurate results, and it also has more stringent requirements for the sampling swabs and transporting before inoculation \[[@B21],[@B22]\]. Therefore, cell culture is rarely used in clinics. Among the available immunological methods, serological tests for the *C. trachomatis* antibody have significant limitations \[[@B23]\], but methods for *C. trachomatis* antigen detection (mainly referring to the lipopolysaccharide, LPS), especially immunochromatography-based methods, have been widely used due to their simplicity of operation. There are two ways to extract the LPS antigen for *C. trachomatis* immunochromatographic assays: heat extraction and acid extraction. Neither of these methods guarantees the full extraction of LPS as an intact antigen, which influences the sensitivity of this method. The biochemical detection of glycogen in *C. trachomatis* inclusions \[[@B24]\] is greatly affected by *Candida spp*. that often exist in these specimens and are especially common during the female menstrual cycle and pregnancy. With the increasing glycogen in vaginal epithelial cells, this method may also cause false positives. The detection of *C. trachomatis* in the United States and Europe has mainly focused on molecular biology methods \[[@B25]-[@B30]\]. Although these methods are both high sensitivity and high specificity, it can be challenging for molecular biology methods to meet the requirements of the actual application in clinical screening.

Enzymatic studies of *C. trachomatis,* especially for enzymes with diagnostic significance, have not been reported in the literature. Previous studies \[[@B31]\] and our research have shown that *C. trachomatis* secretes extracellular enzymes with high α-D-mannosidase activity. Although some organisms used in the study such as *C. albicans* have genes encoding α-1,2-mannosidase \[[@B32]\], α-D-mannosidase activity was invisible by naked eyes with 6-chloro-3-indolyl-α-D-mannoside as substrate. This may be because the extracellular α-D-mannosidase from these organisms is much less or the enzyme activity is relatively low. Previous records \[[@B31],[@B33]-[@B35]\] on substrates of α-D-mannosidase mainly involved p-nitrophenol-α-D-mannoside and 4-methylumbelliferyl-α-D-mannoside. However, 6-chloro-3-indolyl-α-D-mannoside is a novel chromogenic substrate, and colour reaction of its chromogen is much more sensitive especially in the case of the presence of an azo reagent such as fast violet B salt.

Our results showed that clinical specimens such as urethral discharge, cervical secretions, and vaginal secretions did not interfere with the chromogenic detection of α-D-mannosidase activity to screen for *C. trachomatis*, although prostate massage liquid produced more false positive results. Some human sperm surface proteins possess α-D-mannosidase activity \[[@B36]\], which may be the reason that prostate specimens produce less reliable results. Serotype D was only one of the most prevalent (11.1%), and no serovar L2 was found in China \[[@B37]\]. Although the results of this study suggested that other serotypes, such as serotypes E, F, G, K, H, J, I, and Ba, at least most of them, might have α-D-mannosidase activity, there seems to be some limitation of tests on *C. trachomatis* cultures based on only one strain of serotype D. Further studies and more comprehensive clinical evaluations should be conducted due to little research on α-D-mannosidase activity of *C. trachomatis*. In addition, our studies did not evaluate *C. pneumoniae* or *C. psittaci*; the α-D-mannosidase activities of these species should be studied as well.

Conclusions
===========

The present study demonstrated that there were no significant differences between the enzymatic method and the reference method when prostate specimens were excluded. Therefore, α-D-mannosidase activity may be a useful marker for *C. trachomatis* in urogenital tract specimens, with many advantages, such as its speed, ease of use, convenience, and need for no special equipment. Taken together, these data show that the enzymatic method has great potential as a clinical method for *C. trachomatis* screening.
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